Genmab A (GMAB) Other Operating Expenses (2020 - 2026)
Genmab A's (GMAB) quarterly Other Operating Expenses came in at -$65.0 million in Q1 2026, down 54.76% YoY from -$143.7 million in Q1 2025, and up 58.6% on a QoQ basis from -$157.0 million in Q3 2025.
Genmab A (GMAB) Other Operating Expenses (2020 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Other Operating Expenses data on file, last reported at -$65.0 million in Q1 2026.
- Quarterly Other Operating Expenses fell 54.76% year-over-year to -$65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$321.0 million (down 67.19% YoY) and the FY2025 annual result came in at $423.0 million, up 84.72% from the prior year.
- Other Operating Expenses improved to -$65.0 million in Q1 2026, from -$157.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $2.0 billion in Q4 2023 to a low of -$157.0 million in Q3 2025.
- A 4-year average of $185.1 million and a median of -$60.0 million in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2025 — Other Operating Expenses slumped 80.0% — and 2026, when it plunged 54.76%.
- Tracing GMAB's Other Operating Expenses over 4 years: stood at $2.0 billion in 2023, then tumbled by 104.7% to -$95.0 million in 2024, then slumped by 65.26% to -$157.0 million in 2025, then surged by 58.6% to -$65.0 million in 2026.
- The last three Other Operating Expenses figures came in at -$65.0 million (Q1 2026), -$157.0 million (Q3 2025), and -$99.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.00 Mn |
| Mar 31, 2026 | -65.00 Mn |
| Sep 30, 2025 | -157.00 Mn |
| Jun 30, 2025 | -99.00 Mn |
| Mar 31, 2025 | -42.00 Mn |
| Sep 30, 2024 | -95.00 Mn |
| Jun 30, 2024 | -55.00 Mn |
| Mar 31, 2024 | -27.00 Mn |
| Dec 31, 2023 | 2.02 Bn |
| Mar 31, 2021 | -76.00 Mn |
| Mar 31, 2020 | -2.00 Mn |